t
Eight Persons Discharging Managerial Responsibilities (PDMRs) and one Person Closely Associated (PCA) with a PDMR at GSK plc acquired Ordinary Shares under the Company's Share Reward Plan. These transactions occurred on August 11, 2026, on the London Stock Exchange. Seven individuals each acquired 14 Ordinary Shares and one individual acquired 12 Ordinary Shares, all at a price of £19.3496 per share.
| Date | 13 Aug 2026 |
| Time | 15:33:39 |
| Category | Director/PDMR dealings |
| ID | 6275Q |
GSK plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Lynn Baxter |
|||
|
b) |
Position/status |
President, Europe |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.3496 |
7 (partnership shares) |
|
||
|
|
£19.3496 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £19.3496 |
||||
|
e) |
Date of the transaction |
2026-08-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Julie Brown |
|||
|
b) |
Position/status |
Chief Financial Officer |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.3496 |
7 (partnership shares) |
|
||
|
|
£19.3496 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £19.3496 |
||||
|
e) |
Date of the transaction |
2026-08-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
James Ford |
|||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.3496 |
7 (partnership shares) |
|
||
|
|
£19.3496 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £19.3496 |
||||
|
e) |
Date of the transaction |
2026-08-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
David Redfern |
|||
|
b) |
Position/status |
President, Corporate Development |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.3496 |
7 (partnership shares) |
|
||
|
|
£19.3496 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £19.3496 |
||||
|
e) |
Date of the transaction |
2026-08-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Regis Simard |
|||
|
b) |
Position/status |
President, Global Supply Chain |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.3496 |
7 (partnership shares) |
|
||
|
|
£19.3496 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £19.3496 |
||||
|
e) |
Date of the transaction |
2026-08-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Philip Thomson |
|||
|
b) |
Position/status |
President, Global Affairs |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.3496 |
7 (partnership shares) |
|
||
|
|
£19.3496 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £19.3496 |
||||
|
e) |
Date of the transaction |
2026-08-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Deborah Waterhouse |
|||
|
b) |
Position/status |
CEO, ViiV Healthcare and President, Global Health, GSK |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.3496 |
7 (partnership shares) |
|
||
|
|
£19.3496 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £19.3496 |
||||
|
e) |
Date of the transaction |
2026-08-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Victoria Whyte |
|||
|
b) |
Position/status |
SVP & Company Secretary |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.3496 |
6 (partnership shares) |
|
||
|
|
£19.3496 |
6 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
12 Ordinary Shares £19.3496 |
||||
|
e) |
Date of the transaction |
2026-08-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Neil Falkingham |
|||
|
b) |
Position/status |
PCA of Lynn Baxter (President, Europe) |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£19.3496 |
7 (partnership shares) |
|
||
|
|
£19.3496 |
7 (matching shares) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
|
|||
|
Aggregated volume Price |
14 Ordinary Shares £19.3496 |
||||
|
e) |
Date of the transaction |
2026-08-11 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG